James B Rowe Frcp

List of Publications by Year
in descending order

357	25,237	6233 80	11581 135
papers	citations	h-index	g-index

437	437	437	23784
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	2.2	1,402
2	The Prefrontal Cortex: Response Selection or Maintenance Within Working Memory?. Science, 2000, 288, 1656-1660.	6.0	822
3	Activations related to â€œmirrorâ€•and â€œcanonicalâ€•neurones in the human brain: an fMRI study. NeuroImage, 2003, 18, 928-937.	2.1	661
4	Feeling the Beat: Premotor and Striatal Interactions in Musicians and Nonmusicians during Beat Perception. Journal of Neuroscience, 2009, 29, 7540-7548.	1.7	473
5	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	4.9	432
6	The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing. BMC Neurology, 2014, 14, 204.	0.8	430
7	Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology, 2016, 86, 1736-1743.	1.5	383
8	Inpatient general medicine is evidence based. Lancet, The, 1995, 346, 407-410.	6.3	374
9	Characterizing mild cognitive impairment in incident Parkinson disease. Neurology, 2014, 82, 308-316.	1.5	359
10	Active maintenance in prefrontal area 46 creates distractor-resistant memory. Nature Neuroscience, 2002, 5, 479-484.	7.1	346
11	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
12	Large C9orf72 Hexanucleotide Repeat Expansions Are Seen in Multiple Neurodegenerative Syndromes and Are More Frequent Than Expected in the UK Population. American Journal of Human Genetics, 2013, 92, 345-353.	2.6	297
13	Neural activity associated with monitoring the oscillating threat value of a tarantula. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20582-20586.	3.3	294
14	Lateralized Cognitive Processes and Lateralized Task Control in the Human Brain. Science, 2003, 301, 384-386.	6.0	293
15	Attention to action in Parkinsonâ€™s disease. Brain, 2002, 125, 276-289.	3.7	283
16	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	5.8	263
17	Acute Remapping within the Motor System Induced by Low-Frequency Repetitive Transcranial Magnetic Stimulation. Journal of Neuroscience, 2003, 23, 5308-5318.	1.7	262
18	Motor imagery after stroke: Relating outcome to motor network connectivity. Annals of Neurology, 2009, 66, 604-616.	2.8	247

#	Article	IF	Citations
19	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain, 2019, 142, 2558-2571.	3.7	219
20	Inflammation and cerebral small vessel disease: A systematic review. Ageing Research Reviews, 2019, 53, 100916.	5.0	213
21	Motion or activity: their role in intra- and inter-subject variation in fMRI. NeuroImage, 2005, 26, 960-964.	2.1	208
22	Finding and Feeling the Musical Beat: Striatal Dissociations between Detection and Prediction of Regularity. Cerebral Cortex, 2013, 23, 913-921.	1.6	207
23	The Mini-Addenbrooke's Cognitive Examination: A New Assessment Tool for Dementia. Dementia and Geriatric Cognitive Disorders, 2015, 39, 1-11.	0.7	202
24	Attention to Action: Specific Modulation of Corticocortical Interactions in Humans. NeuroImage, 2002, 17, 988-998.	2.1	195
25	Working Memory for Location and Time: Activity in Prefrontal Area 46 Relates to Selection Rather than Maintenance in Memory. NeuroImage, 2001, 14, 77-86.	2.1	192
26	Patients with focal arm dystonia have increased sensitivity to slow-frequency repetitive TMS of the dorsal premotor cortex. Brain, 2003, 126, 2710-2725.	3.7	191
27	Tau burden and the functional connectome in Alzheimerâ€™s disease and progressive supranuclear palsy. Brain, 2018, 141, 550-567.	3.7	190
28	Baseline and longitudinal grey matter changes in newly diagnosed Parkinsonâ€™s disease: ICICLE-PD study. Brain, 2015, 138, 2974-2986.	3.7	188
29	Extrinsic and Intrinsic Brain Network Connectivity Maintains Cognition across the Lifespan Despite Accelerated Decay of Regional Brain Activation. Journal of Neuroscience, 2016, 36, 3115-3126.	1.7	185
30	The Prefrontal Cortex Achieves Inhibitory Control by Facilitating Subcortical Motor Pathway Connectivity. Journal of Neuroscience, 2015, 35, 786-794.	1.7	184
31	Neural Abnormalities in Early-Onset and Adolescence-Onset Conduct Disorder. Archives of General Psychiatry, 2010, 67, 729.	13.8	179
32	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Movement Disorders, 2017, 32, 955-971.	2.2	179
33	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
34	¹⁸F-AV-1451 positron emission tomography in Alzheimerâ€™s disease and progressive supranuclear palsy. Brain, 2017, 140, aww340.	3.7	174
35	Initial Demonstration of in Vivo Tracing of Axonal Projections in the Macaque Brain and Comparison with the Human Brain Using Diffusion Tensor Imaging and Fast Marching Tractography. NeuroImage, 2002, 15, 797-809.	2.1	171
36	The effect of ageing on f<scp>MRI</scp>: Correction for the confounding effects of vascular reactivity evaluated by joint f<scp>MRI</scp> and <scp>MEG</scp> in 335 adults. Human Brain Mapping, 2015, 36, 2248-2269.	1.9	169

#	Article	IF	Citations
37	Parkinson's disease and dopaminergic therapyâ€"differential effects on movement, reward and cognition. Brain, 2008, 131, 2094-2105.	3.7	168
38	The size, burden and cost of disorders of the brain in the UK. Journal of Psychopharmacology, 2013, 27, 761-770.	2.0	163
39	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	1.5	151
40	Neuroinflammation and Functional Connectivity in Alzheimer's Disease: Interactive Influences on Cognitive Performance. Journal of Neuroscience, 2019, 39, 7218-7226.	1.7	145
41	Changes of Cortico-striatal Effective Connectivity during Visuomotor Learning. Cerebral Cortex, 2002, 12, 1040-1047.	1.6	141
42	The default mode network is disrupted in parkinson's disease with visual hallucinations. Human Brain Mapping, 2014, 35, 5658-5666.	1.9	138
43	Cognition in corticobasal syndrome and progressive supranuclear palsy: A review. Movement Disorders, 2014, 29, 684-693.	2.2	137
44	Imaging the mental components of a planning task. Neuropsychologia, 2001, 39, 315-327.	0.7	131
45	Neurotransmitter deficits from frontotemporal lobar degeneration. Brain, 2018, 141, 1263-1285.	3.7	129
46	Dynamic causal modelling of effective connectivity from fMRI: Are results reproducible and sensitive to Parkinson's disease and its treatment?. NeuroImage, 2010, 52, 1015-1026.	2.1	128
47	Effects of Acute Tryptophan Depletion on Prefrontal-Amygdala Connectivity While Viewing Facial Signals of Aggression. Biological Psychiatry, 2012, 71, 36-43.	0.7	128
48	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	4.9	128
49	Genetic impact on cognition and brain function in newly diagnosed Parkinsonâ€™s disease: ICICLE-PD study. Brain, 2014, 137, 2743-2758.	3.7	127
50	Selection and stopping in voluntary action: A meta-analysis and combined fMRI study. NeuroImage, 2014, 86, 381-391.	2.1	123
51	Frequency specific changes in regional cerebral blood flow and motor system connectivity following rTMS to the primary motor cortex. NeuroImage, 2005, 26, 164-176.	2.1	121
52	Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology, 2013, 64, 490-495.	2.0	121
53	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	2.2	121
54	Personality Predicts the Brain's Response to Viewing Appetizing Foods: The Neural Basis of a Risk Factor for Overeating. Journal of Neuroscience, 2009, 29, 43-51.	1.7	119

#	Article	IF	Citations
55	Multiple Modes of Impulsivity in Parkinson's Disease. PLoS ONE, 2014, 9, e85747.	1.1	116
56	Targeting impulsivity in Parkinsonâ€™s disease using atomoxetine. Brain, 2014, 137, 1986-1997.	3.7	116
57	The Prefrontal Cortex shows Context-specific Changes in Effective Connectivity to Motor or Visual Cortex during the Selection of Action or Colour. Cerebral Cortex, 2004, 15, 85-95.	1.6	114
58	Selective serotonin reuptake inhibition modulates response inhibition in Parkinsonâ€™s disease. Brain, 2014, 137, 1145-1155.	3.7	113
59	Microglial activation and tau burden predict cognitive decline in Alzheimerâ€™s disease. Brain, 2020, 143, 1588-1602.	3.7	113
60	Cue integration and the perception of action in intentional binding. Experimental Brain Research, 2013, 229, 467-474.	0.7	109
61	Apathy and impulsivity in frontotemporal lobar degeneration syndromes. Brain, 2017, 140, 1792-1807.	3.7	109
62	In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings. Ageing Research Reviews, 2017, 36, 50-63.	5.0	107
63	Evidence for causal top-down frontal contributions to predictive processes in speech perception. Nature Communications, 2017, 8, 2154.	5.8	107
64	What â€œWorksâ€•in Working Memory? Separate Systems for Selection and Updating of Critical Information. Journal of Neuroscience, 2009, 29, 13735-13741.	1.7	106
65	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	0.9	106
66	Social cognitive deficits and their neural correlates in progressive supranuclear palsy. Brain, 2012, 135, 2089-2102.	3.7	105
67	Genetic screening in sporadic ALS and FTD. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1042-1044.	0.9	105
68	A Head View-Invariant Representation of Gaze Direction in Anterior Superior Temporal Sulcus. Current Biology, 2011, 21, 1817-1821.	1.8	103
69	White matter pathology in Parkinson's disease: The effect of imaging protocol differences and relevance to executive function. NeuroImage, 2012, 62, 1675-1684.	2.1	102
70	Changes in â€œTop-Downâ€•Connectivity Underlie Repetition Suppression in the Ventral Visual Pathway. Journal of Neuroscience, 2011, 31, 5635-5642.	1.7	101
71	Ageing increases reliance on sensorimotor prediction through structural and functional differences in frontostriatal circuits. Nature Communications, 2016, 7, 13034.	5.8	101
72	Cognitive Training Using a Novel Memory Game on an iPad in Patients with Amnestic Mild Cognitive Impairment (aMCI). International Journal of Neuropsychopharmacology, 2017, 20, 624-633.	1.0	100

#	Article	IF	Citations
73	Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain, 2018, 141, 3415-3427.	3.7	95
74	The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 544-551.	0.9	94
75	R47H TREM2 variant increases risk of typical earlyâ€onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimer's and Dementia, 2014, 10, 602.	0.4	94
76	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	4.5	94
77	Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes. Brain, 2020, 143, 1555-1571.	3.7	94
78	Improving Response Inhibition in Parkinsonâ€™s Disease with Atomoxetine. Biological Psychiatry, 2015, 77, 740-748.	0.7	93
79	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	2.2	93
80	Hierarchical Organization of Frontotemporal Networks for the Prediction of Stimuli across Multiple Dimensions. Journal of Neuroscience, 2015, 35, 9255-9264.	1.7	92
81	The role of highâ€field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. Movement Disorders, 2017, 32, 510-525.	2.2	92
82	Connectivity from the ventral anterior cingulate to the amygdala is modulated by appetitive motivation in response to facial signals of aggression. NeuroImage, 2008, 43, 562-570.	2.1	91
83	[¹¹ C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. Neurology, 2018, 90, e1989-e1996.	1.5	89
84	Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinsonâ€™s disease. Brain, 2016, 139, 161-173.	3.7	88
85	Aging is associated with contrasting changes in local and distant cortical connectivity in the human motor system. NeuroImage, 2006, 32, 747-760.	2.1	85
86	Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Movement Disorders, 2015, 30, 141-149.	2.2	84
87	The functional neuroimaging correlates of psychogenic versus organic dystonia. Brain, 2013, 136, 770-781.	3.7	83
88	Direct Gaze Elicits Atypical Activation of the Theory-of-Mind Network in Autism Spectrum Conditions. Cerebral Cortex, 2014, 24, 1485-1492.	1.6	81
89	The role of noradrenaline in cognition and cognitive disorders. Brain, 2021, 144, 2243-2256.	3.7	81
90	A synergistic core for human brain evolution and cognition. Nature Neuroscience, 2022, 25, 771-782.	7.1	80

#	Article	IF	Citations
91	Dissociable mechanisms of speed-accuracy tradeoff during visual perceptual learning are revealed by a hierarchical drift-diffusion model. Frontiers in Neuroscience, 2014, 8, 69.	1.4	79
92	Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. Neurobiology of Aging, 2016, 48, 153-160.	1.5	79
93	The neural signature of escalating frustration in humans. Cortex, 2014, 54, 165-178.	1.1	77
94	[¹⁸F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1032-1037.	0.9	77
95	Separating vascular and neuronal effects of age on fMRI BOLD signals. Philosophical Transactions of the Royal Society B: Biological Sciences, 2021, 376, 20190631.	1.8	77
96	Atomoxetine restores the response inhibition network in Parkinsonâ€™s disease. Brain, 2016, 139, 2235-2248.	3.7	76
97	â€˜Under pressureâ€™: is there a link between orthostatic hypotension and cognitive impairment in Î±-synucleinopathies?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1311-1321.	0.9	75
98	Idiosyncratic responding during movie-watching predicted by age differences in attentional control. Neurobiology of Aging, 2015, 36, 3045-3055.	1.5	74
99	Noradrenergic-dependent functions are associated with age-related locus coeruleus signal intensity differences. Nature Communications, 2020, 11, 1712.	5.8	74
100	Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans. Neuropsychopharmacology, 2018, 43, 2645-2651.	2.8	72
101	Connectivity Analysis Reveals a Cortical Network for Eye Gaze Perception. Cerebral Cortex, 2010, 20, 1780-1787.	1.6	71
102	Choosing the Rules: Distinct and Overlapping Frontoparietal Representations of Task Rules for Perceptual Decisions. Journal of Neuroscience, 2013, 33, 11852-11862.	1.7	71
103	Improving response inhibition systems in frontotemporal dementia with citalopram. Brain, 2015, 138, 1961-1975.	3.7	71
104	Convergent evidence for hierarchical prediction networks from human electrocorticography and magnetoencephalography. Cortex, 2016, 82, 192-205.	1.1	71
105	In vivo rate-determining steps of tau seed accumulation in Alzheimerâ€™s disease. Science Advances, 2021, 7, eabh1448.	4.7	70
106	Generating animal and tool names: An fMRI study of effective connectivity. Brain and Language, 2005, 93, 32-45.	0.8	69
107	Activity and Connectivity Differences Underlying Inhibitory Control Across the Adult Life Span. Journal of Neuroscience, 2018, 38, 7887-7900.	1.7	69
108	Connectivity analysis is essential to understand neurological disorders. Frontiers in Systems Neuroscience, 2010, 4, .	1.2	68

#	Article	IF	Citations
109	Neuroinflammation in Lewy body dementia. Parkinsonism and Related Disorders, 2015, 21, 1398-1406.	1.1	68
110	Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. Brain, 2020, 143, 1010-1026.	3.7	68
111	Action selection: A race model for selected and non-selected actions distinguishes the contribution of premotor and prefrontal areas. NeuroImage, 2010, 51, 888-896.	2.1	67
112	PET Tau and Amyloid-Î² Burden in Mild Alzheimerâ€™s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2017, 60, 283-293.	1.2	67
113	The medial frontal-prefrontal network for altered awareness and control of action in corticobasal syndrome. Brain, 2014, 137, 208-220.	3.7	66
114	Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans. Brain, 2015, 138, 1658-1666.	3.7	65
115	Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. BMJ Open, 2017, 7, e013187.	0.8	65
116	Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia. Brain, 2018, 141, 2486-2499.	3.7	64
117	Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimerâ€™s disease, frontotemporal dementia and progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 651-658.	0.9	64
118	An fMRI study of the neural correlates of graded visual perception. NeuroImage, 2006, 31, 1711-1725.	2.1	63
119	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. NeuroImage: Clinical, 2017, 15, 171-180.	1.4	63
120	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	4.9	62
121	The acute brain response to levodopa heralds dyskinesias in Parkinson disease. Annals of Neurology, 2014, 75, 829-836.	2.8	61
122	Synaptic Loss in Primary Tauopathies Revealed by [<scp>¹¹C</scp>]<scp>UCBâ€‰</scp> Positron Emission Tomography. Movement Disorders, 2020, 35, 1834-1842.	2.2	61
123	Attention to action: specific modulation of corticocortical interactions in humans. NeuroImage, 2002, 17, 988-98.	2.1	61
124	Emotion recognition in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1143-1145.	0.9	60
125	Selection and inhibition mechanisms for human voluntary action decisions. NeuroImage, 2012, 63, 392-402.	2.1	60
126	Predicting beneficial effects of atomoxetine and citalopram on response inhibition in <scp>P</scp>arkinson's disease with clinical and neuroimaging measures. Human Brain Mapping, 2016, 37, 1026-1037.	1.9	60

#	Article	IF	Citations
127	Neurophysiological signatures of Alzheimerâ€™s disease and frontotemporal lobar degeneration: pathology versus phenotype. Brain, 2018, 141, 2500-2510.	3.7	60
128	Neuroinflammatory and morphological changes in late-life depression: the NIMROD study. British Journal of Psychiatry, 2016, 209, 525-526.	1.7	59
129	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. Movement Disorders, 2016, 31, 1062-1066.	2.2	59
130	iElectrodes: A Comprehensive Open-Source Toolbox for Depth and Subdural Grid Electrode Localization. Frontiers in Neuroinformatics, 2017, 11, 14.	1.3	58
131	Is the Prefrontal Cortex Necessary for Establishing Cognitive Sets?. Journal of Neuroscience, 2007, 27, 13303-13310.	1.7	57
132	Multi-modal MRI investigation of volumetric and microstructural changes in the hippocampus and its subfields in mild cognitive impairment, Alzheimer's disease, and dementia with Lewy bodies. International Psychogeriatrics, 2017, 29, 545-555.	0.6	56
133	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	3.8	56
134	Rule-Selection and Action-Selection have a Shared Neuroanatomical Basis in the Human Prefrontal and Parietal Cortex. Cerebral Cortex, 2008, 18, 2275-2285.	1.6	55
135	Reversed Frontotemporal Connectivity During Emotional Face Processing in Remitted Depression. Biological Psychiatry, 2012, 72, 604-611.	0.7	55
136	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	3.7	55
137	GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition. Brain, 2020, 143, 3449-3462.	3.7	55
138	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 612-621.	0.9	55
139	Parahippocampal Reactivation Signal at Retrieval after Interruption of Rehearsal. Journal of Neuroscience, 2002, 22, 6315-6320.	1.7	54
140	Different Neural Mechanisms within Occipitotemporal Cortex Underlie Repetition Suppression across Same and Different-Size Faces. Cerebral Cortex, 2013, 23, 1073-1084.	1.6	54
141	Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinsonâ€™s disease. Brain, 2021, 144, 2513-2526.	3.7	53
142	Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity. Neurobiology of Disease, 2011, 43, 79-85.	2.1	52
143	The motor system and its disorders. NeuroImage, 2012, 61, 464-477.	2.1	52
144	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.5	52

#	Article	IF	Citations
145	Dementia wellbeing and COVIDâ€19: Review and expert consensus on current research and knowledge gaps. International Journal of Geriatric Psychiatry, 2021, 36, 1597-1639.	1.3	52
146	The neural basis of effective memory therapy in a patient with limbic encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1202-1205.	0.9	51
147	The effects of age on restingâ€state BOLD signal variability is explained by cardiovascular and cerebrovascular factors. Psychophysiology, 2021, 58, e13714.	1.2	51
148	An in vivo probabilistic atlas of the human locus coeruleus at ultra-high field. NeuroImage, 2021, 225, 117487.	2.1	50
149	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. Neurobiology of Aging, 2017, 55, 78-90.	1.5	48
150	The Impact of Neurodegeneration on Network Connectivity: A Study of Change Detection in Frontotemporal Dementia. Journal of Cognitive Neuroscience, 2013, 25, 802-813.	1.1	47
151	Beyond the Ã¢â‚¬Å“urge to moveÃ¢â‚¬Â• objective measures for the study of agency in the post-Libet era. Frontiers in Human Neuroscience, 2014, 8, 450.	1.0	47
152	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	1.5	47
153	The Dementias Platform UK (DPUK) Data Portal. European Journal of Epidemiology, 2020, 35, 601-611.	2.5	45
154	Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinsonâ€™s Disease. Neuropsychopharmacology, 2016, 41, 2171-2177.	2.8	43
155	Gait in Mild Alzheimerâ€™s Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. Journal of Alzheimer's Disease, 2018, 63, 331-341.	1.2	42
156	Prognostic importance of apathy in syndromes associated with frontotemporal lobar degeneration. Neurology, 2019, 92, e1547-e1557.	1.5	42
157	Age-related reduction in motor adaptation: brain structural correlates and the role of explicit memory. Neurobiology of Aging, 2020, 90, 13-23.	1.5	42
158	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	2.8	42
159	How Does Reward Expectation Influence Cognition in the Human Brain?. Journal of Cognitive Neuroscience, 2008, 20, 1980-1992.	1.1	41
160	Reorganisation of brain networks in frontotemporal dementia and progressive supranuclear palsy. NeuroImage: Clinical, 2013, 2, 459-468.	1.4	41
161	Serotonin 2A Receptors, Citalopram and Tryptophan-Depletion: a Multimodal Imaging Study of their Interactions During Response Inhibition. Neuropsychopharmacology, 2013, 38, 996-1005.	2.8	41
162	The role of the amygdala during emotional processing in Huntington's disease: From pre-manifest to late stage disease. Neuropsychologia, 2015, 70, 80-89.	0.7	41

#	Article	IF	Citations
163	[¹⁸F]AVâ€1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation. Annals of Clinical and Translational Neurology, 2016, 3, 940-947.	1.7	41
164	Comparison of arterial spin labeling registration strategies in the multiâ€center GENetic frontotemporal dementia initiative (GENFI). Journal of Magnetic Resonance Imaging, 2018, 47, 131-140.	1.9	41
165	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain, 2019, 142, 1108-1120.	3.7	41
166	Language impairment in progressive supranuclear palsy and corticobasal syndrome. Journal of Neurology, 2021, 268, 796-809.	1.8	41
167	Action-blindsight in healthy subjects after transcranial magnetic stimulation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1353-1357.	3.3	40
168	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	1.5	40
169	Neuroinflammation predicts disease progression in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 769-775.	0.9	40
170	Playing it safe but losing anywayâ€"Serotonergic signaling of negative outcomes in dorsomedial prefrontal cortex in the context of risk-aversion. European Neuropsychopharmacology, 2013, 23, 919-930.	0.3	39
171	Network mechanisms of intentional learning. NeuroImage, 2016, 127, 123-134.	2.1	39
172	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
173	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <scp>GENFI</scp> cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	1.7	39
174	Strong and specific associations between cardiovascular risk factors and white matter micro- and macrostructure in healthy aging. Neurobiology of Aging, 2019, 74, 46-55.	1.5	38
175	Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy. Annals of Neurology, 2020, 88, 1194-1204.	2.8	38
176	In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 45-52.	0.9	38
177	The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease. Neurobiology of Aging, 2010, 31, 1064-1068.	1.5	37
178	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	2.2	37
179	Serotonin 2A receptors contribute to the regulation of risk-averse decisions. NeuroImage, 2013, 83, 35-44.	2.1	36
180	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.4	36

#	Article	IF	Citations
181	Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals. Neurobiology of Aging, 2015, 36, 1519-1528.	1.5	35
182	Longitudinal diffusion tensor imaging changes in early Parkinsonâ€™s disease: ICICLE-PD study. Journal of Neurology, 2018, 265, 1528-1539.	1.8	35
183	Seeing what you want to see: priors for one's own actions represent exaggerated expectations of success. Frontiers in Behavioral Neuroscience, 2014, 8, 232.	1.0	34
184	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. Alzheimer's Research and Therapy, 2018, 10, 46.	3.0	34
185	Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics. Neurobiology of Aging, 2020, 92, 141-152.	1.5	34
186	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	2.1	33
187	Managing cognition in progressive supranuclear palsy. Neurodegenerative Disease Management, 2016, 6, 499-508.	1.2	32
188	Dynamic targeting enables domain-general inhibitory control over action and thought by the prefrontal cortex. Nature Communications, 2022, 13, 274.	5.8	32
189	Direction-Sensitive Codes for Observed Head Turns in Human Superior Temporal Sulcus. Cerebral Cortex, 2012, 22, 735-744.	1.6	31
190	Perseveration and Choice in Parkinson's Disease: The Impact of Progressive Frontostriatal Dysfunction on Action Decisions. Cerebral Cortex, 2013, 23, 1572-1581.	1.6	31
191	White matter change with apathy and impulsivity in frontotemporal lobar degeneration syndromes. Neurology, 2018, 90, e1066-e1076.	1.5	31
192	Neuroanatomical substrates of generalized brain dysfunction in COVID-19. Intensive Care Medicine, 2021, 47, 116-118.	3.9	31
193	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.4	31
194	Cortical Complexity Analyses and Their Cognitive Correlate in Alzheimerâ€™s Disease and Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 76, 331-340.	1.2	31
195	Parkinson's disease and healthy aging: Independent and interacting effects on action selection. Human Brain Mapping, 2010, 31, 1886-1899.	1.9	30
196	Sensory attenuation in Parkinsonâ€™s disease is related to disease severity and dopamine dose. Scientific Reports, 2018, 8, 15643.	1.6	30
197	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 301-309.	1.2	30
198	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 768-773.	0.9	29

#	Article	IF	Citations
199	Meta-analytic Evidence for the Plurality of Mechanisms in Transdiagnostic Structural MRI Studies of Hallucination Status. EClinicalMedicine, 2019, 8, 57-71.	3.2	29
200	Characterizing the Clinical Features and Atrophy Patterns of MAPT -Related Frontotemporal Dementia With Disease Progression Modeling. Neurology, 2021, 97, e941-e952.	1.5	29
201	Modafinil Improves Episodic Memory and Working Memory Cognition in Patients With Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 115-122.	1.1	28
202	Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort. Journal of Alzheimer's Disease, 2018, 65, 1-16.	1.2	28
203	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	1.4	28
204	Artificial grammar learning in vascular and progressive non-fluent aphasias. Neuropsychologia, 2017, 104, 201-213.	0.7	27
205	Hippocampal Stratum Radiatum, Lacunosum, and Moleculare Sparing in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 61, 415-424.	1.2	27
206	In vivo evidence for preâ€symptomatic neuroinflammation in a <scp>MAPT</scp> mutation carrier. Annals of Clinical and Translational Neurology, 2019, 6, 373-378.	1.7	27
207	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	1.4	27
208	GABA-ergic Dynamics in Human Frontotemporal Networks Confirmed by Pharmaco-Magnetoencephalography. Journal of Neuroscience, 2020, 40, 1640-1649.	1.7	27
209	Synaptic density in carriers of C9orf72 mutations: a [¹¹C]UCBâ€J PET study. Annals of Clinical and Translational Neurology, 2021, 8, 1515-1523.	1.7	27
210	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	3.7	27
211	The effect of a history of conduct disorder in adult major depression. Journal of Affective Disorders, 1996, 37, 51-63.	2.0	26
212	Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloidâ€positive mild cognitive impairment is associated with key clinical features. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 690-699.	1.2	26
213	Evidence of a Causal Association Between Cancer and Alzheimerâ€™s Disease: a Mendelian Randomization Analysis. Scientific Reports, 2019, 9, 13548.	1.6	26
214	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	1.1	26
215	Magnetoencephalography of frontotemporal dementia: spatiotemporally localized changes during semantic decisions. Brain, 2011, 134, 2513-2522.	3.7	25
216	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 975-984.	0.9	25

#	Article	IF	Citations
217	A Longitudinal Study of Motor, Oculomotor and Cognitive Function in Progressive Supranuclear Palsy. PLoS ONE, 2013, 8, e74486.	1.1	24
218	InÂvivo coupling of tau pathology and cortical thinning in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 678-687.	1.2	24
219	Biomagnetic biomarkers for dementia: A pilot multicentre study with a recommended methodological framework for magnetoencephalography. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 450-462.	1.2	24
220	ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloidâ€Î² copathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 277-280.	1.2	24
221	Parkinsonism in frontotemporal dementias. International Review of Neurobiology, 2019, 149, 249-275.	0.9	24
222	Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity. Acta Neuropathologica Communications, 2020, 8, 11.	2.4	24
223	Peak Width of Skeletonized Mean Diffusivity as a Marker of Diffuse Cerebrovascular Damage. Frontiers in Neuroscience, 2020, 14, 238.	1.4	24
224	GABAergic cortical network physiology in frontotemporal lobar degeneration. Brain, 2021, 144, 2135-2145.	3.7	24
225	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
226	Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimerâ€™s disease: systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1080-1090.	0.9	24
227	AÎ²42/AÎ²40 and AÎ²42/AÎ²38 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimerâ€™s Disease: A Pilot Study. Journal of Alzheimer's Disease, 2018, 65, 1377-1383.	1.2	23
228	Education modulates brain maintenance in presymptomatic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1124-1130.	0.9	23
229	Locus Coeruleus Integrity from <scp>7â€‰T MRI</scp> Relates to Apathy and Cognition in Parkinsonian Disorders. Movement Disorders, 2022, 37, 1663-1672.	2.2	23
230	Functional biomarkers for neurodegenerative disorders based on the network paradigm. Progress in Neurobiology, 2011, 95, 505-509.	2.8	22
231	Physical Activity Predicts Population-Level Age-Related Differences in Frontal White Matter. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 236-243.	1.7	22
232	Clinical Conditions â€œSuggestive of Progressive Supranuclear Palsyâ€â€”Diagnostic Performance. Movement Disorders, 2020, 35, 2301-2313.	2.2	22
233	Looking beneath the surface: the importance of subcortical structures in frontotemporal dementia. Brain Communications, 2021, 3, fcab158.	1.5	22
234	Evidence and implications of abnormal predictive coding in dementia. Brain, 2021, 144, 3311-3321.	3.7	22

#	Article	IF	Citations
235	Heteroplasmic mitochondrial DNA mutations in frontotemporal lobar degeneration. Acta Neuropathologica, 2022, 143, 687-695.	3.9	22
236	An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntingtonâ€™s disease. Journal of Neurology, 2017, 264, 2457-2463.	1.8	21
237	Connectomics and molecular imaging in neurodegeneration. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2819-2830.	3.3	21
238	18F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy. Journal of Neurology, 2020, 267, 341-349.	1.8	21
239	In vivo PET imaging of neuroinflammation in familial frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 319-322.	0.9	21
240	Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study. Brain, 2022, 145, 340-348.	3.7	21
241	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
242	Acute serotonin 2A receptor blocking alters the processing of fearful faces in the orbitofrontal cortex and amygdala. Journal of Psychopharmacology, 2013, 27, 903-914.	2.0	20
243	Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease. Movement Disorders, 2016, 31, 1163-1172.	2.2	20
244	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	1.5	20
245	Multi-centre, multi-vendor reproducibility of 7T QSM and R2* in the human brain: Results from the UK7T study. NeuroImage, 2020, 223, 117358.	2.1	20
246	[¹⁸F]AVâ€1451 binding is increased in frontotemporal dementia due to C9orf72 expansion. Annals of Clinical and Translational Neurology, 2018, 5, 1292-1296.	1.7	19
247	Ventricular volume expansion in presymptomatic genetic frontotemporal dementia. Neurology, 2019, 93, e1699-e1706.	1.5	19
248	Anterior temporal lobe is necessary for efficient lateralised processing of spoken word identity. Cortex, 2020, 126, 107-118.	1.1	19
249	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	2.8	19
250	In Vivo Assay of Cortical Microcircuitry in Frontotemporal Dementia: A Platform for Experimental Medicine Studies. Cerebral Cortex, 2021, 31, 1837-1847.	1.6	19
251	Noradrenergic deficits contribute to apathy in Parkinsonâ€™s disease through the precision of expected outcomes. PLoS Computational Biology, 2022, 18, e1010079.	1.5	19
252	The impact of brain imaging technology on our understanding of motor function and dysfunction. Current Opinion in Neurobiology, 1999, 9, 728-734.	2.0	18

#	Article	IF	Citations
253	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimerâ€™s disease. BMJ Open, 2019, 9, e024498.	0.8	18
254	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	0.7	18
255	Relationship between tau, neuroinflammation and atrophy in Alzheimer's disease: The NIMROD study. Information Fusion, 2021, 67, 116-124.	11.7	18
256	Predicting loss of independence and mortality in frontotemporal lobar degeneration syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 737-744.	0.9	18
257	11C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies. European Journal of Hybrid Imaging, 2020, 4, 25.	0.6	18
258	The binaural masking level difference: cortical correlates persist despite severe brain stem atrophy in progressive supranuclear palsy. Journal of Neurophysiology, 2014, 112, 3086-3094.	0.9	17
259	European Ultrahighâ€Field Imaging Network for Neurodegenerative Diseases (EUFIND). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 538-549.	1.2	17
260	Tackling gaps in developing lifeâ€changing treatments for dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 241-253.	1.8	17
261	Effect of apolipoprotein E polymorphism on cognition and brain in the Cambridge Centre for Ageing and Neuroscience cohort. Brain and Neuroscience Advances, 2020, 4, 239821282096170.	1.8	17
262	Correlation of microglial activation with white matter changes in dementia with Lewy bodies. NeuroImage: Clinical, 2020, 25, 102200.	1.4	17
263	In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies. Neurobiology of Aging, 2021, 101, 187-198.	1.5	17
264	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. NeuroImage, 2019, 188, 282-290.	2.1	16
265	Falls in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2020, 7, 16-24.	0.8	16
266	Functional localization and categorization of intentional decisions in humans: A meta-analysis of brain imaging studies. NeuroImage, 2021, 242, 118468.	2.1	16
267	Prefrontal Cortical Connectivity Mediates Locus Coeruleus Noradrenergic Regulation of Inhibitory Control in Older Adults. Journal of Neuroscience, 2022, 42, 3484-3493.	1.7	16
268	Conversion disorder: understanding the pathogenic links between emotion and motor systems in the brain. Brain, 2010, 133, 1295-1297.	3.7	15
269	Imaging Psychogenic Movement Disorders. Current Neurology and Neuroscience Reports, 2013, 13, 402.	2.0	15
270	Cognitive Diversity in a Healthy Aging Cohort: Cross-Domain Cognition in the Cam-CAN Project. Journal of Aging and Health, 2020, 32, 1029-1041.	0.9	15

#	Article	IF	Citations
271	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. Movement Disorders, 2021, 36, 503-508.	2.2	15
272	Apathy is associated with reduced precision of prior beliefs about action outcomes.. Journal of Experimental Psychology: General, 2020, 149, 1767-1777.	1.5	15
273	A â€˜Mini Linguistic State Examinationâ€™ to classify primary progressive aphasia. Brain Communications, 2022, 4, fcab299.	1.5	15
274	Cortical neuroplasticity in patients recovering from acute optic neuritis. NeuroImage, 2008, 42, 836-844.	2.1	14
275	Dopaminergic modulation of positive expectations for goal-directed action: evidence from Parkinsonâ€™s disease. Frontiers in Psychology, 2015, 6, 1514.	1.1	14
276	Towards accurate and unbiased imaging-based differentiation of Parkinsonâ€™s disease, progressive supranuclear palsy and corticobasal syndrome. Brain Communications, 2020, 2, fcaa051.	1.5	14
277	Alien limb syndrome: A Bayesian account of unwanted actions. Cortex, 2020, 127, 29-41.	1.1	14
278	Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography. Neurobiology of Aging, 2021, 101, 172-180.	1.5	14
279	Dorsal Prefrontal Cortex: Maintenance in Memory or Attentional Selection?. , 2002, , 221-232.		14
280	Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies. International Journal of Clinical Pharmacology and Therapeutics, 2020, 58, 426-438.	0.3	14
281	Causal Evidence for the Multiple Demand Network in Change Detection: Auditory Mismatch Magnetoencephalography across Focal Neurodegenerative Diseases. Journal of Neuroscience, 2022, 42, 3197-3215.	1.7	14
282	Gray matter changes related to microglial activation in Alzheimer's disease. Neurobiology of Aging, 2020, 94, 236-242.	1.5	13
283	A Modified Progressive Supranuclear Palsy Rating Scale. Movement Disorders, 2021, 36, 1203-1215.	2.2	13
284	Neurophysiological and Brain Structural Markers of Cognitive Frailty Differ from Alzheimer's Disease. Journal of Neuroscience, 2022, 42, 1362-1373.	1.7	13
285	A Winding Road: Alzheimerâ€™s Disease Increases Circuitous Functional Connectivity Pathways. Frontiers in Computational Neuroscience, 2015, 9, 140.	1.2	12
286	Neuroticism predicts the impact of serotonin challenges on fear processing in subgenual anterior cingulate cortex. Scientific Reports, 2018, 8, 17889.	1.6	12
287	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion carriers in the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1325-1328.	0.9	12
288	Metabolomic changes associated with frontotemporal lobar degeneration syndromes. Journal of Neurology, 2020, 267, 2228-2238.	1.8	12

#	Article	IF	Citations
289	Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants. Brain Communications, 2021, 3, fcab206.	1.5	12
290	Advances in neuroimaging to support translational medicine in dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 263-270.	0.9	12
291	Progressive supranuclear palsy: diagnosis and management. Practical Neurology, 2021, 21, 376-383.	0.5	12
292	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	3.0	12
293	FRONTotemporal dementia Incidence European Research Studyâ€"FRONTIERS: Rationale and design. Alzheimer's and Dementia, 2022, 18, 498-506.	0.4	12
294	Development of a sensitive trial-ready poly(GP) CSF biomarker assay forC9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 761-771.	0.9	12
295	Systemic idazoxan impairs performance in a non-reversal shift test: implications for the role of the central noradrenergic systems in selective attention. Journal of Psychopharmacology, 1996, 10, 188-194.	2.0	11
296	Research paper does not show causal link between benzodiazepine use and diagnosis of dementia. BMJ, The, 2012, 345, e7984-e7984.	3.0	11
297	The neural signature of information regularity in temporally extended event sequences. NeuroImage, 2015, 107, 266-276.	2.1	11
298	Alien limb in the corticobasal syndrome: phenomenological characteristics and relationship to apraxia. Journal of Neurology, 2020, 267, 1147-1157.	1.8	11
299	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	1.2	11
300	Language Disorder in Progressive Supranuclear Palsy and Corticobasal Syndrome: Neural Correlates and Detection by the MLSE Screening Tool. Frontiers in Aging Neuroscience, 2021, 13, 675739.	1.7	11
301	The Test Your Memory for Mild Cognitive Impairment (TYM-MCI). Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1045-1051.	0.9	10
302	Atomoxetine and citalopram alter brain network organization in Parkinsonâ€™s disease. Brain Communications, 2019, 1, fcz013.	1.5	10
303	Test Your Memory (TYM) and Test Your Memory for Mild Cognitive Impairment (TYM-MCI): A Review and Update Including Results of Using the TYM Test in a General Neurology Clinic and Using a Telephone Version of the TYM Test. Diagnostics, 2019, 9, 116.	1.3	10
304	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 608-616.	0.9	10
305	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	0.7	10
306	Proton magnetic resonance spectroscopy in frontotemporal lobar degeneration-related syndromes. Neurobiology of Aging, 2022, 111, 64-70.	1.5	10

#	Article	IF	Citations
307	11 Câ€PK11195 PET imaging and white matter changes in Parkinsonâ€™s disease dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2133-2136.	1.7	9
308	InÂVivo ¹⁸F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy. Journal of Nuclear Medicine, 2022, 63, 1052-1057.	2.8	9
309	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	4.4	9
310	Coactivation sign in fixed dystonia. Parkinsonism and Related Disorders, 2013, 19, 474-476.	1.1	8
311	Test Your Memory (TYM test): diagnostic evaluation of patients with non-Alzheimer dementias. Journal of Neurology, 2019, 266, 2546-2553.	1.8	8
312	Altered network stability in progressive supranuclear palsy. Neurobiology of Aging, 2021, 107, 109-117.	1.5	8
313	Altered structural connectivity networks in dementia with lewy bodies. Brain Imaging and Behavior, 2021, 15, 2445-2453.	1.1	8
314	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	1.4	8
315	The pre-supplementary motor area achieves inhibitory control by modulating response thresholds. Cortex, 2022, 152, 98-108.	1.1	8
316	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. Neurology, 2020, 95, e3288-e3302.	1.5	7
317	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 158-168.	0.9	7
318	Prediagnostic Progressive Supranuclear Palsy â€“ Insights from the UK Biobank. Parkinsonism and Related Disorders, 2022, 95, 59-64.	1.1	7
319	Dataâ€driven staging of genetic frontotemporal dementia using multiâ€modal <scp>MRI</scp>. Human Brain Mapping, 2022, 43, 1821-1835.	1.9	7
320	A multi-site, multi-participant magnetoencephalography resting-state dataset to study dementia: The BioFIND dataset. NeuroImage, 2022, 258, 119344.	2.1	7
321	Coâ€Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2021, 8, 1225-1233.	0.8	6
322	Editorial. Brain, 2020, 143, 1-1.	3.7	5
323	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.5	5
324	Role of brain imaging in early parkinsonism. BMJ: British Medical Journal, 2011, 342, d638-d638.	2.4	4

#	Article	IF	Citations
325	Parsing the Roles of the Frontal Lobes and Basal Ganglia in Task Control Using Multivoxel Pattern Analysis. Journal of Cognitive Neuroscience, 2017, 29, 1390-1401.	1.1	4
326	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	1.6	4
327	Disorders of Volition from Neurological Disease. , 2015, , 389-414.		4
328	The basal ganglia in cognitive disorders. , 2016, , 69-80.		4
329	Prefrontal cortex and attention to action. , 0, , 263-286.		4
330	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	3.0	4
331	DOPAMINE TRANSPORTER (DAT) IMAGING CAN BE NORMAL WITH NEUROPATHOLOGICALLY CONFIRMED CORTIOBASAL DEGENERATION. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.59-e2.	0.9	3
332	The white elephant revived: A new marriage between PET and MRI. NeuroImage, 2014, 84, 1104-1106.	2.1	3
333	Imaging Tau, Neuroinflammation, and AÎ² in Dementia With Lewy Bodies: A Deepâ€Phenotyping Case Report. Movement Disorders Clinical Practice, 2019, 6, 77-80.	0.8	3
334	The revised Addenbrooke's Cognitive Examination can facilitate differentiation of dementia with Lewy bodies from Alzheimer's disease. International Journal of Geriatric Psychiatry, 2021, 36, 831-838.	1.3	3
335	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	1.5	3
336	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. Journal of Alzheimer's Disease, 2022, , 1-14.	1.2	3
337	[P4â€“189]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1337.	0.4	2
338	Predict Disease Progression With Reaction Rate Equation Modeling of Multimodal MRI and PET. Frontiers in Aging Neuroscience, 2018, 10, 306.	1.7	2
339	[18F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases. Brain Communications, 2021, 3, fcab177.	1.5	2
340	The Dementia UK Ecosystem: a call to action. Lancet Neurology, The, 2021, 20, 699-700.	4.9	2
341	Clinicopathological co-occurrence of Fahrâ€™s disease and dementia with Lewy bodies. , 2020, 39, 227-231.		2
342	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	1.1	2

#	Article	IF	Citations
343	Editorial. Brain, 2015, 138, 2461-2462.	3.7	1
344	Reply: Brain oscillations, inhibition and social inappropriateness in frontotemporal degeneration. Brain, 2018, 141, e74-e74.	3.7	1
345	A â€˜Mini Linguistic State Examinationâ€™ to Classify Primary Progressive Aphasia. SSRN Electronic Journal, 0, , .	0.4	1
346	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 336-339.	0.9	1
347	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. SSRN Electronic Journal, 0, , .	0.4	1
348	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
349	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. Journal of Neurology, 2022, 269, 4322-4332.	1.8	1
350	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	1.7	1
351	Parahippocampal reactivation failure leads to forgetting independently of encoding failure. NeuroImage, 2001, 13, 734.	2.1	0
352	Editorial. Brain, 2015, 138, 505-506.	3.7	0
353	Disease-informed brain mapping teaches important lessons about the human brain. NeuroImage, 2019, 190, 1-3.	2.1	0
354	Noradrenergic contributions to cognitive decline and treatment potential in progressive supranuclear palsy and Parkinsonâ€™s disease. Alzheimer's and Dementia, 2020, 16, e044767.	0.4	0
355	A case report of metastatic renal cell carcinoma causing corticobasal syndrome. , 2021, 40, 160-164.		0
356	Editorial. Brain, 2020, 143, 381-382.	3.7	0
357	Are the UK genetic testing criteria for dementia too exclusive?. Journal of Neurology, 2021, , 1.	1.8	0